Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.

Abstract

Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply "liquid biopsy" strategies in children with cancer, it is important to tailor our efforts to the unique genomic features of these tumors and address the technical and logistical challenges of integrating biomarker testing. This article reviews the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies and suggests new directions for future studies.

• Authors: Samuel D Abbou, David S Shulman, Steven G DuBois, Brian D Crompton
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 66 Issue 5 Pg. e27595 (05 2019) ISSN: 1545-5017 [Electronic] United States
• PMID: 30614191 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2019 Wiley Periodicals, Inc.

Chemical References

• Biomarkers, Tumor
• Circulating Tumor DNA

Topics

• Biomarkers, Tumor (analysis, genetics)
• Circulating Tumor DNA (analysis, genetics)
• Humans
• Liquid Biopsy
• Neoplasms (blood, diagnosis, genetics)
• Precision Medicine